Cooper Companies (NASDAQ:COO) Price Target Lowered to $110.00 at JPMorgan Chase & Co.

Cooper Companies (NASDAQ:COO) had its price target decreased by JPMorgan Chase & Co. from $120.00 to $110.00 in a report released on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical device company’s stock.

Several other analysts have also recently issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Friday. StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Morgan Stanley decreased their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a report on Friday, December 6th. Citigroup dropped their price target on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research note on Friday. Finally, Wells Fargo & Company upped their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $111.89.

Cooper Companies Stock Down 6.6 %

Shares of COO opened at $85.00 on Friday. The firm has a market cap of $16.96 billion, a P/E ratio of 43.59, a P/E/G ratio of 2.25 and a beta of 1.02. Cooper Companies has a 1 year low of $82.61 and a 1 year high of $112.38. The stock has a 50 day simple moving average of $92.52 and a two-hundred day simple moving average of $99.45. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. On average, analysts forecast that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cooper Companies

Institutional investors have recently made changes to their positions in the company. Ashton Thomas Securities LLC bought a new position in Cooper Companies in the 3rd quarter valued at approximately $25,000. Byrne Asset Management LLC purchased a new position in shares of Cooper Companies in the fourth quarter worth $33,000. OFI Invest Asset Management purchased a new position in shares of Cooper Companies in the fourth quarter worth $34,000. Covestor Ltd lifted its holdings in shares of Cooper Companies by 144.9% during the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 200 shares in the last quarter. Finally, New Age Alpha Advisors LLC purchased a new stake in shares of Cooper Companies during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.